MOL2150 Simplexa HSV 1&2 Direct -CSF -Genital Swab -Cutaneous /… — Class II medical device recall Z-2547-2020
Terminated recall by DiaSorin Molecular LLC, reported 2020-07-22, distributed nationwide. Due to a software malfunction in the Multi Assay Suite, there is the probability of increased occurrence of fa
| Recall number | Z-2547-2020 |
|---|---|
| Product type | Medical device |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | DiaSorin Molecular LLC, Cypress, CA, United States |
| Recall initiated | 2020-05-12 |
| Classified | 2020-07-10 |
| Reported by FDA | 2020-07-22 |
| Terminated | 2024-04-19 |
| Distributed | Nationwide (US) |
| Countries outside the US | AT, CZ, FR |
| Reason classes | potency, device malfunction, software |
Product
MOL2150 Simplexa HSV 1&2 Direct -CSF -Genital Swab -Cutaneous / Mucocutaneous Swabs Product Usage: is intended for use on the LIAISON MDX instrument for the qualitative detection and differentiation of HSV-1 and HSV-2 present in cerebrospinal fluid (CSF), or cutaneous and mucocutaneous lesion swabs from patients with signs and symptoms of HSV-1 or HSV-2 infection of the central nervous system (CNS) or cutaneous and mucocutaneous lesions.
Reason for recall
Due to a software malfunction in the Multi Assay Suite, there is the probability of increased occurrence of false negative results.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/Z-2547-2020. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.